Leveraging Retinal Organoids to Advance Animal-Free Drug Testing for Ocular Cancer

4:45 pm - Thursday 29th January 2026

  • Developing multi-molecular therapeutics to enhance efficacy against late-stage ocular melanoma compared to single-drug approaches
  • Harnessing nature-derived compounds to discover novel anti-cancer agents for safer and more effective ocular therapeutics
  • Adopting FDA-compliant organoid systems to eliminate animal testing while meeting FDA Modernization Act 2.0 requirements

Speakers:

Co-Founder & Chief Executive Officer
Phythera Therapeutics